WO2025087383 - COMPOUND ACTING AS PARP7 INHIBITOR
National phase entry:
Publication Number
WO/2025/087383
Publication Date
01.05.2025
International Application No.
PCT/CN2024/127356
International Filing Date
25.10.2024
Title **
[English]
COMPOUND ACTING AS PARP7 INHIBITOR
[French]
COMPOSÉ AGISSANT EN TANT QU'INHIBITEUR DE PARP7
[Chinese]
作为PARP7抑制剂的化合物
Applicants **
DOVETREE MEDICINES UNUS, INC.
Inventors
GAO, Fang
FANG, Xiaoniu
NIU, Chunyi
HUA, Zihao
WANG, Shaohui
CHEN, Bin
ZHANG, Peiyu
Priority Data
202311406408.4
26.10.2023
CN
202410735258.X
06.06.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4032 | |
| EPO | Filing, Examination, Granting | 29152 | |
| Japan | Filing, Examination, Granting | 2831 | |
| South Korea | Filing, Examination, Granting | 3631 | |
| USA | Filing, Examination, Granting | 9490 |
Total:
49,136
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a biaromatic compound acting as a PARP7 inhibitor. Specifically, the present invention relates to a compound of formula (I), or an enantiomer, diastereomer, racemate, tautomer, stereoisomer, geometric isomer, nitrogen oxide, metabolite or pharmaceutically acceptable salt, ester, solvate, hydrate, isotope-labeled compound or prodrug thereof. The present invention also relates to a use of the compound for treating or preventing PARP7-mediated diseases, such as cancer, immune diseases, inflammation or viral infections.[French]
La présente invention concerne un composé biaromatique agissant en tant qu'inhibiteur de PARP7. Plus particulièrement, la présente invention concerne un composé de formule (I), ou un énantiomère, un diastéréoisomère, un racémate, un tautomère, un stéréoisomère, un isomère géométrique, un oxyde d'azote, un métabolite ou un sel, un ester, un solvate, un hydrate, un composé marqué par un isotope ou un promédicament pharmaceutiquement acceptable de celui-ci. La présente invention concerne également une utilisation du composé pour le traitement ou la prévention de maladies médiées par PARP7, telles que le cancer, les maladies immunitaires, l'inflammation ou les infections virales.[Chinese]
本发明涉及作为PARP7抑制剂的联芳香化合物。具体而言，本发明涉及式（I）的化合物或其对映异构体、非对映异构体、消旋体、互变异构体、立体异构体、几何异构体、氮氧化物、代谢产物或其药学上可接受的盐、酯、溶剂化物、水合物、同位素标记化合物或前药。本发明还涉及所述化合物用于治疗或预防PARP7介导的疾病，例如癌症、免疫性疾病、炎症或病毒感染的用途。